• Researchers are Actively Seeking Treatments or A Cure for Alzheimer’s Disease
  • One Current Research Avenue Is to Look at Currently-Approved Medications that are used for other desire, an approach that is street Drugposing.
  • A New Study you identified two cancer medications that May Help Overturn Brain Changes Caused by Alzheimer’s Disease, possibly Slowing or Even Reversing the Disease’s Symptoms.

Rewers All Over The World Are Activeley Seeking Treatments Or A Cure For Alzheimer’s Disease – A Form of Dementia Currently Impacting About 32 Million People GLOBALLY.

The Medications used right now for Alzheimer’s Disease Are Designed to Only Help Treat Symptoms and Slow Disease Progression.

One Avenue Scientists are Taking in an Effort to Find Treatments for Alzheimer’s Disease Is by Looking at Currently-Approved Medications that are used for other desire, an approach street Drug Repurposing.

“The idea of drarug repurposition or identifying new uses for existing drarugs, can spere the drarug discovery process the compounds already have been tested for toxicity and adverse Events,” Marina Sirota, PHD, Professor and Interim Director of the University of California – San Francisco Bak Bakar Computational Health Sciences Institute Explained To Medical News Today.

“Alzheimer’s Disease is a complex disease, which is very difficult to treat so we need to use all the tools possible to Speed Up Drug Discovery and Help Patients,” Said Sirota Sirota

Sirota is The Co-Senior Author of A New Study Recently Published in the Journal CellThat have identified two cancer medications that may helic overturn brain changes caused by Alzheimer’s Disease, possibly slowing or Even Reversing the Disease’s Symptoms.

Focusing on Cancer Drugs Letrozole and Irinotecan

For This Study, Began By Using Past Studies to Assess Alzheimer’s Disease Changed Gene Expression in Brain Cells, Mainly Neurons and Glia.

“Glia Cells Are Non-Neuronal Cells That provides Support and Protection to Neurons in the Nervous System,” Sirota Explanined. “By Targeting Bothic Cells and Non-Neuronal Cells (Glia) We Hope To Be Uble to More Comprehensive Target Disease Pathophysiology.”

From there, Scientists The Took the Gene Expression Signatures They Found and used Database streets the connectivitymap, Allowing Them to examine Thousands of Drugs to Find Uones that revealed The Alzheimer’s Disease Gene Expression Signature.

“We started with a set of 1,300 Drugs and narrowed it download to the combination of letrozole and irinotecan Through Data Driven Analysis Using Breeh Molecular and Clinical Data,” Sirota Said.

“We First Identified Compounds that revealed The Cell Type Specific Disease Signatures Back To Normal Based On The Gene Expression Profiles. We The Further filtered the list to the candidates that AFFFECT severe Cell Types,” She explained.

“The We Wted to See Whether Patients Who Are On Those Drugs Already Have Lower Risk of Alzheimer’s Disease By Querying Electronic Medical Records Across The UC System,” She continues. “This has allowed US to narrow ur listing to a handful of drarugs and focus on this combination.”

The Analysis of Electronic Medical Records Did Indeed Show That Drugs Were Associated With A Significantly Lower Risk of Alzheimer’s Disease, Confirmg The Selection.

Combo of Cancer Drugs Reverses Brain Cell Damage, you reduce Build-up protein in mouse model

Next, Refectchers decided with the combination of letrozole – used to treat breast cancer – and irinotecan – used to treat colorectal and lung cancer – in a mouse model of grindersive Alzheimer’s Disease.

At the Study’s Conclusion, Sirota and Her Team Found That the Drug Combination Overturned Multiple Aspects of Alzheimer’s Disease in the Mouse Model, including undenging the gene expression signature changes in the neurons and glia caused by the ease.

Addionione Amyloid-Beta And Tau Proteins in the Brain, which are Known Hallmarks of Alzheimer’s Disease.

“This Tells Us That Multiple Levels of Evidence – Molecular Data, Clinical Information and Mouse Model Experiments Are Alligning To Tell Us That Tosee Compounds Might Be Helpful for Alzheimer’s Disease Patients,” Sirota Said.

She Further Noted That:

“While we don’t know the exact mechanism of How before Drugs Work To Treat Alzheimer’s Disse DNA TOPOISOMERASE I.Specifically Targeting The S and G2 Phases of the Cell Cycle. LETROZOLE’S MECHANISM OF Action Inhibiting The Enzyme aromatasewhich is crucial in the biosynthesis of estrogen. “

“However, We Don’t Know Whether it is the main aphorementionec mechanisms or off-target Effects of these Drugs Which Might Help Alzheimer’s Disease Patients,” Sirota Cautioned. “Additional experiments need to be carried out to Better Understand HowSe Two Drugs Might Work Together to Combat Alzheimer’s Disease in patients.”

Using ‘Big Data’ and Inventive Approaches to Find Potential Alzheimer’s Drug Targets

MNT Had the Opportunity To Speak with John Dickson, MD, PHD, A Neurologist at Massachusetts General Hospital, About This Research.

“This is an interesting and innovative Paper that uses ‘Big data’ to aid in identify potential dragets to treat alzheimer’s disease and then tests candidates in a preclinical model of Alzheimer’s Disease,” Dickson, Who Was Not Involved in This Research, Said.

“Combining the use of transcriptomic data from Brain Tissue from Alzheimer’s Disease Patients, Drug Disturbation Studies in Cell Lines, and Patient Data From Electronic Medical Records Was An Inventive Approach to Identifying and Narrowing Down Potential Drug Targets,” I have add. “

In Dickson’s View, “The Decision to use Dual-Therapy Approach and Plan to Target Multiple Cell Types With This Strategy was also innovative.”

“The Combination of Drugs Showed Benefit Effects On The Memory Testing and Neuropathological Findings In A Mouse Model of Alzheimer’s Disease. In Addition to Identifying Two potential Variety of Conditions, ”I have continued.

WHY LOOK AT REPURPOSING EXISTING DRUGS FOR ALZHEIMER’S TREATMENT?

MNT Also Talked to Clifford Segil, Do, A Neurologist at Providence Saint John’s Health Center in Santa Monica, Ca, About This Study, Who Said It Is Refreshing To See Data That Supports Import Vecting Memory Loss This Brain Acetylcholine, N-Methyl-D-Aspartate (NMDA)or Amyloid.

“This Study’s Design is Smart and the Data is Captivating,” Segil, Who Likewise was not involved in the Research, Added. “REPURPOSING MEDICATIONS ALREADY BEING USED HAS BEEN Extremely Rewarding in Neurologists and I TRULY HOPE SOMETHING GROWS OUT OF THIS REESARCH.”

And Peter Gliebus, MD, Neurologist and Director of Cognitive and Behavioral Neurology at Marcus Neuroscience Institute, Part of Baptist Health South Florida, Also Not Involved in the Research, Commeable To MNT That This was promising and exciting study, and said that repurposition existing Drugs offers severe adventages.

“Faster Development Since sincere Drugs Already have established Safety Profiles, Which reduces the time and cost required for clinical trials,” Gliebus Noted.

“Cost-effectiveness (Is Achieved) by avoiding The High Expensses Associated With Developing New Drugs from Scratch. And (This Approach Has) A Broader Impact, as many existing drugs may have anxplored mechalanisms that could addres addres addres alzheimer alzheimer Pathologies, Such as Neuroinflammation, Synaptic Dysfunction, and Metabolic Deficits. “

“Given The High Failure Rate of Alzheimer’s Drug Trials, Repurposition Provides to Practical and Efficient Pathway to Identify Effective Treatments,” The Neurologist Conclluded.